NCT03708224View on ClinicalTrials.gov

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
CancerCarcinomaSquamous Cell CarcinomaHead and Neck Cancer
Interventions
BIOLOGICAL

Atezolizumab

Given intravenously (IV)

BIOLOGICAL

Tocilizumab

Given IV

BIOLOGICAL

Tiragolumab

Given IV

Trial Locations (1)

94143

RECRUITING

University of San Francisco, California, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

American Head and Neck Society

OTHER

lead

Alain Algazi

OTHER